A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HH-006 in Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Huahui Health is developing a treatment for Hepatitis B virus. This study is designed to
evaluate the safety and tolerability of HH-006, a hepatitis virus neutralizing monoclonal
antibody in healthy volunteers, and to determine its pharmacokinetic profile and
immunogenicity.